Among the melanoma patient cohort who received anti-CTLA-4 checkpoint blockade therapy, we observed a reduction in the gene expression level of NLRC5-dependent MHC class I and CD8+ T cell genes in non-responders versus responders (Fig. 1a). The gene discussed is NLRC5; the disease is melanoma.